Drug Profile
PHIN 1138
Alternative Names: PHIN-1138Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator PharmaIN
- Class Heart failure therapies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Heart failure in USA (unspecified route), prior to September 2023 (PharmaIN pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Heart-failure in USA